was treated with high flow O2, I/V ionotrope and fluid to maintain her BP and continuous monitoring of vitals including central venous pressure monitoring. Her cardiac markers were inconclusive; S. Troponin-I 0.22 ng/ml. X-ray chest showed no significant abnormality. Serial ECG showed gradual appearance of S1Q3T3 changes, suggestive of massive Pulmonary Embolism. Bedside echo showed dilated RA and RV with RV free wall hypokinesia and systolic dysfunction with moderately high Pulmonary systolic pressure (60 mmHg). LV was normal in size with good regional and global wall motion. D-dimer was 821 mic gm/ lit. Immediately CT Pulmonary Angiogram was done. It revealed a saddle thrombus in the bifurcation of main pulmonary artery extending into the both branches ( Fig. 1, 2) . Bilateral segmental and subsegmental branches involved having acute thrombus within causing partial obliteration of lumen with no definite cut off. Right sided pleural effusion with early basal atelectatic changes. Lower limbs Doppler showed Acute to early subacute thrombosis in right Popliteal vein. She had a significant past history of Guillain-Barre' Syndrome (GBS) with significant paraparesis of lower limbs for which she was admitted in same hospital 2 months back and discharged home with advice of regular physiotherapy of lower limbs. During this admission she also had to take assist from other during walking. Her treatment started conservatively with IV heparin & fluids. I/V thrombolysis was deferred due to high risk of complications like intracerebral haemorrage.
The following day as her BP was not raising with adequate inotropes, pulse rate was > 130/min and low volume and her O2 saturation was not maintaining with out high flow through mask and her chest discomfort and short of breath persisted, she was advised for Surgical thrombectomy and was immediately transferred to department of CT Surgery on same day. Clots were removed surgically under cardiopulmonary bypass (Fig. 3,  4) . By Fogerty emboletomy rest of the clots removed from distal branches. SVC transected to gain access to RPA. RPA opened by longitudinal incision. More clots found here and removed directly and by Fogerty embolectomy. Both the PAs flushed by heparin saline. RPA and LPA closed directly. Her postoperative period was uneventful. From 2 nd POD LMWH twice daily with Aspirin/ clopidogrel and warfarin were started. On 4 th POD she was shifted to cabin. Then we planned to implant an IVC filter to protect further recurrence of PE. 
Discussion:
Venous thromboembolism (VTE) has an incidence of approximately 100 individuals per 100,000 population each year in the United States. 4 The most common presentation of VTE is deep venous thrombosis (DVT) or its more feared complication, pulmonary embolism (PE). Each year VTE is responsible for the deaths of at least 100,000 to 200,000 patients in the United States who have an otherwise good prognosis and whose deaths could likewise be preventable. 5 First described in the 1800s, pulmonary embolism can be classified as acute or chronic, as submassive (25%-50% obstruction) or massive (>50% obstruction), and as central or peripheral. 6 Acute pulmonary embolism leads to an abrupt rise in pulmonary vascular resistance. Right ventricular contractile function is compromised, and right ventricular failure ensues. This vicious cycle of cardiogenic shock is augmented by concomitant hypoxia, which inevitably leads to cardiovascular collapse. 7 The interval from the onset of symptoms to death is relatively short. In patients with massive pulmonary embolism, 50% die within 30 minutes, 70% die within 1 hour, and more than 85% die within 6 hours of the onset of symptoms. 8 The principals of treatment of massive PE includes reducing the clot burden by thrombolysis or mechanical removal and prevention of further clot production (DVT by anticoagulation -heparin and warfarin) and clot migration by caval filter insertion. 9 Treatment options for massive pulmonary embolism vary, depending on the clinical picture of the patient. Although anticoagulation and thrombolysis are the standard for treatment of acute massive pulmonary embolism, these treatments are limited to patients who are hemodynamically stable and do not have contraindications. Furthermore, data suggest that patients treated with thrombolysis have a higher death rate, increased risk of major hemorrhage, and increased rates of recurrence of pulmonary embolism, compared with patients treated by means of pulmonary embolectomy. 10 The International Cooperative Pulmonary Embolism Registry found a surprisingly high intracranial hemorrhage rate of 3% among patients with pulmonary embolism who were treated with thrombolytic therapy. 11 However, these procedures are associated with an increased risk of hemorrhage, recurrent emboli, and failure to completely resolve the intraluminal thrombus, putting patients at higher risk to develop pulmonary hypertension. 12, 13, 14 Early surgical treatment must also be considered in patients whose course deteriorates in spite of aggressive medical therapy. 15 Depending on the series, the overall mortality rate after pulmonary embolectomy varies from 16% to 46%, with a mean mortality rate of 26%. 6 Ullmann's group reported an operative mortality of 35% in their series. 6 The high mortality rate, for the most part, is due to the fact that most patients who undergo surgical embolectomy are hemodynamically compromised and arrive at the operating room in cardiac arrest with cardiopulmonary resuscitation (CPR) in progress, or else they have had CPR performed beforehand. Data suggest that preoperative hemodynamic status is the most important prognostic indicator of postoperative outcome after surgical pulmonary embolectomy, and cardiac arrest and CPR are independent factors predictive of postoperative death. 6, 15 These findings suggest that earlier surgical intervention may result in improved survival. The present report describes a case in which severe hemodynamic compromise mandated a surgical embolectomy.
Patients with acute PE are at risk for recurrent thromboembolic events, mainly a second PE. The risk of recurrent PE is less than 1% per year while patients are receiving anticoagulant therapy, but the risk is 2 to 10 % per year after the discontinuation of such therapy. 16 Risk factors for recurrence include male sex, advanced age and idiopathic or unprovoked PE can be as high as 50% among patients with PE. The risk of recurrence is particularly high among patients with cancer. The risk of recurrence is about 3% per year among patients in whom the first PE was associated with a temporary risk factor, such as major surgery, immobilization because of an acute medical illness, or trauma. 2 After an acute PE, patients should be monitored for chronic thromboembolic pulmonary hypertension. The incidence of chronic thromboembolic pulmonary hypertension 2 years after the acute event ranges from 0.8 to 3.8%. 17, 18 Vena cava filters were introduced in the 1960s as a mechanical means to prevent PE. 19 Since that time, the number of filters placed has grown steadily to over 40,000 annually in the United States alone. 20 Randomized trials have shown that in addition to heparin therapy, the use of permanent filters initially reduces the occurrence of symptomatic or asymptomatic PE without changes in either immediate or long-term mortality. 21 In this case we decided to implant vena caval filter to prevent further devastating recurrence of PE.
Conclusion:
Massive pulmonary embolism remains a highly fatal disease. An episode of severe hypotension in a patient with deep vein thrombosis and suspected pulmonary embolism requires rapid diagnosis to enable expedient thrombolysis or surgery. As thrombolysis bears higher rates of death, major haemorrhage and recurrent embolism than open pulmonary embolectomy, early referral to a cardiothoracic surgeon should thus be considered in cases of significant embolism. To prevent recurrence early IVC filter implantation may be a good choice to complete the treatment of AMPE.
